Researchers discovered that trans-kingdom small RNAs can protect crops from fungal pathogens, including the causal agent of 'Cotton Cancer'. The study found that specific sRNAs can be expressed in cotton cultivars to confer resistance to Verticillium wilt disease.
A phase III trial found ipilimumab as adjuvant therapy significantly improved overall survival in patients with high-risk stage III melanoma, reducing relative risk of death by 28% at 5.3 years median follow-up.
NASA-NOAA satellites captured detailed images of Hurricane Matthew's cloud tops, revealing temperatures as low as minus 80 F (-62.2 C), indicating strong storm uplift and potential heavy rain generation.
The ENGOT-OV16/NOVA trial shows niraparib significantly improves progression-free survival in recurrent ovarian cancer patients, with median survival rates up to 21 months. Niraparib also improves secondary endpoints, including time to first subsequent treatment and chemotherapy-free interval.
Two phase II trials, KEYNOTE-052 and CheckMate 275, demonstrate the efficacy of PD-1 blockade with pembrolizumab and nivolumab in treating metastatic bladder cancer. The trials show a median survival benefit for patients with high PD-L1 expression.
A nationwide study in France found that the true burden of head and neck cancer is significantly higher than previously estimated. The EPICORL study revealed a five-year survival rate of 34% and a high risk of secondary primary cancers, with distant metastases at diagnosis associated with a six-fold increase in mortality.
The MONALEESA2 study shows a significant improvement in progression-free survival for postmenopausal women with hormone receptor-positive advanced breast cancer when treated with ribociclib plus letrozole. The combination also resulted in higher objective response rates and improved clinical benefits.
By 2025, up to 12 million children may develop impaired glucose tolerance, while 4 million will be diagnosed with type 2 diabetes. The study forecasts a sharp increase in obesity-related conditions among children, sparking calls for governments to reduce childhood obesity.
Researchers found that fulvestrant significantly increases progression-free survival in hormone-receptor-positive advanced breast cancer patients, especially those with lower-volume disease. The treatment also showed similar health-related quality of life compared to anastrozole and was well-tolerated.
A phase I study of BAY 1163877 identified patients who will respond to the pan-FGFR inhibitor based on tumor mRNA expression, with notable activity seen in bladder cancer and adenoid cystic carcinoma. The drug was well-tolerated, revealing a toxicity profile better than other FGFR inhibitors under development.